Tusq DX

Quick links to important sections

Tusq DX

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tusq DX

Quick Facts

Property Description
Active Ingredients Dextromethorphan, Chlorpheniramine, Phenylephrine
Form Oral Liquid (Syrup), Oral Tablet
Pharmacological Class Multicomponent Cough and Cold Relief Agent
General Purpose Symptomatic relief of dry cough, congestion, and allergy
Origin Synthetic (Fixed-Dose Combination)

What is the Pharmacological Class and Type of Tusq DX?

Tusq DX is a Fixed-Dose Combination (FDC) medicinal preparation, categorized broadly as a Multicomponent Cough and Cold Relief Agent. This entirely synthetic product is designed for oral administration and is typically marketed with a focus on comprehensive relief for co-occurring symptoms of upper respiratory tract infections. The structure of this FDC, integrating three distinct actions, is a method clinically recognized for addressing the varied discomforts of the common cold simultaneously.

The Active Ingredients and Available Forms

The composition of Tusq DX is based on three active components: Dextromethorphan Hydrobromide, a non-narcotic antitussive; Chlorpheniramine Maleate, a first-generation H1 antihistamine; and Phenylephrine Hydrochloride, a sympathomimetic agent. Pharmacological studies confirm the role of these specific agents in reducing the severity of non-productive cough, mitigating allergic responses, and alleviating nasal congestion. The medicine is commonly available as an Oral Liquid (Syrup), which is distinguished by its Flavoured Mentholated Syrupy Base, and it is also manufactured in an Oral Tablet form.

General Therapeutic Purpose and Action Profile

The general therapeutic purpose of Tusq DX is to offer coordinated symptomatic management, often for a typical scenario where a patient experiences a persistent dry cough alongside nasal congestion and allergy-related symptoms. The combined actions provide relief: the antitussive component centrally reduces the urge to cough, the antihistamine element mitigates allergy symptoms, and the decongestant works to promote a physical clearing of the upper respiratory passages. This multi-target approach is supported by the consensus among global health authorities on the efficacy of combination therapy for treating multiple cold symptoms concurrently.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Tusq DX?

Official Regulatory Safety Profile

The safety profile for this medicine is based on classifications from official regulatory documents, detailing adverse reactions by frequency and the body systems affected. The most frequently documented adverse reactions primarily involve the Nervous System and the Gastrointestinal Tract.

Classification Examples of Officially Documented Effects
Common Drowsiness, somnolence, dry mouth, sedation, dizziness.
Uncommon Excitability, nervousness, headache, blurred vision, restlessness.

The official labeling notes that these effects, particularly drowsiness and sedation, are often more pronounced at the beginning of treatment.

System-Organ Class and Serious Reactions

The systems most commonly associated with adverse effects in the regulatory profile include Nervous System Disorders, Gastrointestinal Disorders, Cardiac Disorders, and Vascular Disorders. While uncommon, official documents define serious adverse reactions, which include the potential for Severe Hypersensitivity reactions (e.g., anaphylaxis) and clinically significant cardiovascular events like Hypertensive Crisis.

Safety notes also address the potential for Serotonin Syndrome when the antitussive component is used in combination with certain other medicines.

Population-Specific Considerations and Constraints

The regulatory safety profile includes specific considerations for certain patient groups. Older adults are officially noted as being more susceptible to both the CNS effects (e.g., confusion) and cardiovascular effects (e.g., increased blood pressure). Conversely, children may, in some cases, experience paradoxical excitability rather than sedation.

The use of this medication is subject to critical constraints and is contraindicated in individuals with pre-existing conditions such as severe hypertension or severe coronary artery disease. A primary safety restriction is the absolute prohibition against concurrent use with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI).

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived strictly from official government regulatory documents detailing the overdose profile and mandated emergency actions for this medication.

Overdose Scope

Entity Regulator-Documented Statement
Documented overdose presentations Overdose may initially present with excitation, hallucinations, tremors, dizziness, and nystagmus. Severe toxicity involves CNS depression, convulsions, coma, rapid heartbeat, hypertension, and hyperpyrexia (fever).
Physiological systems affected (as stated in label) Central Nervous System, Cardiovascular System, Respiratory System, Gastrointestinal System.
Dose-related or exposure-related factors (if applicable) A large overdose carries risk of respiratory depression. The potential for Serotonin Syndrome is noted in the overdose context.
Population-specific overdose notes (if applicable) In the small child, symptoms may begin with excitation and fever, with a heightened risk for severe outcomes including convulsions and coma.
When immediate medical help is required (label-derived phrasing only) Seek professional help immediately. Contact a Poison Control Center or emergency services if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Classification Type Regulator-Documented Wording
Severity classification (as defined in official documents) Symptoms can progress to severe cases leading to death.
Overdose-context constraints (as defined in official documents) Symptomatic and supportive treatment is the defined management; no single specific antidote is known for the combination product.

Connection to the Overall Overdose Profile

Regulatory documents define the Tusq DX overdose profile by detailing specific, progressive neurological and cardiovascular toxicities that necessitate immediate professional intervention. The official information requires that urgent medical help be sought upon the appearance of severe, life-threatening symptoms, as management is confined to symptomatic and supportive treatment due to the lack of a single known antidote for the combination.

Therapeutic Uses of Tusq DX

Tusq DX is a combination medication used for the temporary management of symptoms associated with upper respiratory issues. It is commonly used when short-term symptomatic assistance is needed to help ease overall discomfort during symptomatic periods. The primary therapeutic areas include addressing symptoms related to the common cold, seasonal allergies, and other minor throat or bronchial irritations.

This combination may assist with managing multiple symptoms simultaneously, providing support that helps ease the overall burden of symptoms. It is relevant for easing symptoms that create noticeable physiological strain, such as an irritative dry cough, runny nose, sneezing, and watery/itchy eyes.


Quick Fact: Relevant for easing symptoms of dry cough, common cold, and allergies.


Patient Benefit

The medicine plays a role in managing conditions characterized by periods of heightened symptoms, assisting with maintaining functional stability when symptoms interfere with routine activities. It contributes to improved comfort during periods of heightened symptoms, helping to ease distress and support general well-being during symptomatic phases.

Regulatory References

  1. DailyMed label for Chlorpheniramine Maleate and Dextromethorphan HBr

Eligibility and Restrictions for Use

The eligibility profile for Tusq DX is strictly defined by regulatory bodies based on age and pre-existing health conditions, establishing absolute prohibitions and conditional use requirements.

Populations Who Must Not Use Tusq DX (Contraindications)

Use is absolutely contraindicated in several high-risk populations, including patients with a known hypersensitivity to any of its components. Individuals who are currently taking or have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days must not use this medicine. It is also prohibited for patients with severe pre-existing conditions, such as severe coronary artery disease and severe hypertension, or specific ocular conditions like narrow-angle glaucoma. Nursing mothers are also categorized as contraindicated populations.

Age and Conditional Eligibility

Use is generally established for adults and children 12 years of age and older. Regulatory agencies advise that the medicine is not recommended for children under 2 years of age due to the lack of established safety and effectiveness data.

Certain populations require conditional use with caution:

  • Older Adults (60 years and older): Due to an increased likelihood of adverse reactions.
  • Organ Impairment: Patients with hepatic or renal impairment.
  • Physiological States: Use during pregnancy is permitted only if the potential benefit justifies the potential risk (Pregnancy Category C).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines documented interactions between the components of Tusq DX (Chlorphenamine, Dextromethorphan, and Phenylephrine) and other medicines or substances, as specified in regulatory documents.

Significant Interaction Categories and Restrictions

Interacting Product Category Official Restriction/Concern Component Affected
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated. Avoid use for at least 14 days after stopping an MAOI. Dextromethorphan, Chlorphenamine
Central Nervous System (CNS) Depressants (e.g., alcohol, hypnotics, sedatives) Use with caution or avoid; risk of additive CNS depression (drowsiness, sedation). Chlorphenamine
Sympathomimetics (e.g., decongestants, appetite suppressants) Avoid concomitant use; risk of additive cardiovascular effects (e.g., increased blood pressure). Phenylephrine
Antihypertensives Sympathomimetic component may reduce the effect of these medicines. Phenylephrine
Cardiac Glycosides (e.g., Digoxin) Use with caution; may increase the risk of irregular heartbeat. Phenylephrine
Ergot Alkaloids (e.g., Ergotamine) Avoid concomitant use; risk of ergotism. Phenylephrine
Grapefruit or Grapefruit Juice Avoid consumption; may increase the risk of side effects. Dextromethorphan

Overview of the Official Interaction Profile

The regulatory profile for this combination medicine is dominated by the contraindication with MAO Inhibitors, which is a mandatory restriction due to the potential for serious reactions, including hyperpyrexia. Other critical constraints involve drugs that potentiate the CNS depressant effects of chlorphenamine and those that exacerbate the cardiovascular stimulant effects of phenylephrine. These documented interaction statements dictate specific restrictions, ranging from complete avoidance to required caution, to manage the risks of excessive sedation, severe hypertensive reactions, or other adverse effects.

Mechanism of Action

The Central Cough Pathway

Tusq DX's mechanism involves the concurrent action of two distinct pharmacological agents. The primary agent acts as a sigma1 receptor agonist in the brain's medulla, which reduces the central transmission of afferent cough signals. This modulation occurs within the medullary cough center itself, altering the signal processing cascade.


H1 Receptor Antagonism

The second component functions as a first-generation H1 receptor antagonist. This antagonist stereochemically competes with histamine for binding sites on H1 receptors located in various tissues, including the respiratory tract and capillary beds. By blocking the binding of endogenous histamine, the mechanism results in decreased histamine-mediated vascular permeability and smooth muscle contraction in the nasal and ocular tissues.

Dosage and Administration Information

The administration of Tusq DX, a fixed-dose combination product, is governed by official instructions detailing the route, dosing schedule, and measurement requirements. It is exclusively for oral administration in the form of a liquid (syrup or solution) or an oral tablet.


Standardized Dosing and Frequency

The usage of this medication is strictly defined by regulatory guidelines to ensure precise intake and limit total daily exposure:

  • Adults and Adolescents (12 years and older): The standard single dose of the oral liquid is typically 10 mL (two teaspoonfuls), or one tablet, administered every 4 hours.
  • Children (6 to under 12 years): The typical dose is 5 mL (one teaspoonful) every 4 hours.
  • Maximum Limit: Administration must not exceed 6 doses within any 24-hour period.

Administration Requirements

Feature Official Instruction
Preparation The oral liquid must be shaken well before measurement to ensure uniform mixing.
Measurement The dose must be measured using a calibrated dosing device (such as a marked spoon or cup), and household utensils must not be substituted.
Timing The medicine may be taken with or without food.
Course Duration Use is intended only for temporary relief of acute symptoms, not for chronic use.

For children under 6 years of age, official labeling instructs users to consult a doctor before administration.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Active Components

Tusq DX is a fixed-dose combination medication whose therapeutic profile is based on the established effects of its three active ingredients:

  • Dextromethorphan: A cough suppressant that research suggests acts centrally to modulate the cough reflex.
  • Chlorpheniramine: An antihistamine, which studies indicate works by blocking histamine receptors to help relieve symptoms associated with allergies and the common cold.
  • Phenylephrine: A decongestant, which is understood to act on blood vessels in the nasal passages to help reduce congestion.

Research Findings and Limitations

Studies focused on the efficacy of combination products for cough and cold symptoms often assess the contribution of each component to overall symptom relief. While the individual agents have documented evidence supporting their roles (antitussive, antihistaminic, and decongestant effects):

Research Area Findings Focus
Symptom Duration Clinical trials have explored whether the combination may influence the duration and severity of symptoms like runny nose, sneezing, and dry cough.
Safety Profile Research primarily reports on the combined known safety profiles and potential adverse events associated with each component, including central nervous system effects such as drowsiness and dizziness.

The combined data from multiple studies are considered when evaluating the risk and benefit profile of this fixed-dose combination. Scientific organizations and regulatory bodies generally emphasize that evidence supporting the use of these over-the-counter cough and cold combinations, particularly in specific populations, remains under ongoing review.

Key Studies & References

  1. Cough and Cold Medicine Misuse: The Role of Dextromethorphan (Review of Clinical and Regulatory Data)
  2. Phenylephrine: A clinical pharmacology review of its use as a nasal decongestant

Frequently Asked Questions (FAQ)

Common questions about Tusq DX (FAQ)


Q: Is Tusq DX used for both wet and dry coughs?

Official documents indicate that this medicine is intended for the symptomatic management of dry coughs associated with colds and allergies. It is generally not indicated for coughs associated with lower respiratory tract conditions, such as asthma or emphysema, or for coughs that produce a lot of mucus or secretions.


Q: Is it normal to feel a bit dizzy after taking Tusq DX?

Official regulatory documents list dizziness and drowsiness as common adverse reactions associated with this type of medicine. Official documentation notes these effects are often more noticeable at the beginning of treatment. If effects become concerning, official guidance on reporting adverse reactions is available.


Q: Does Tusq DX affect the ability to drive or operate machinery?

Regulatory warnings indicate that caution is required when performing tasks that demand mental alertness, such as driving or operating machinery. This is because the medicine may cause effects like drowsiness or blurred vision, which may affect coordination or reaction time.


Q: Can I take Tusq DX if I am taking medication for anxiety or depression?

Official documents advise that the components of this medicine may interact with certain drugs used for depression and anxiety. This includes drugs like MAOIs, which are absolutely contraindicated, and certain other antidepressants like SSRIs, due to the potential risk of effects such as serotonin syndrome or increased sedation. Official guidance emphasizes the importance of understanding all potential interactions before use.


Q: Does Tusq DX work to thin mucus in the chest?

The active components of this medicine include a cough suppressant, an antihistamine, and a decongestant. The product is primarily indicated for dry cough, and its official components do not include an expectorant, which is the class of medicine used to thin and loosen mucus in the chest.


Q: Does official information list any long-term side effects for Tusq DX?

Official guidance describes this medicine as intended for short-term use for temporary symptom relief. The documented safety profiles and official instructions are based on this temporary, short-term administration, and official documents do not describe the safety profile or use for long-term administration.


Q: Can the ingredients in Tusq DX affect a drug test?

Official sources state that the antitussive ingredient, Dextromethorphan, has been known to potentially cause a false-positive result for phencyclidine (PCP) on some initial urine drug screening tests. This fact is included as a documented caution related to the active ingredient.


Q: Does Tusq DX contain an antibiotic?

No. Tusq DX is a multi-component product categorized as a cold and cough relief agent. It contains a cough suppressant, an antihistamine, and a decongestant, and it is not classified as an antibiotic.


Q: Can I take Tusq DX if I have high blood pressure?

Official documents include specific warnings and contraindications for individuals with pre-existing heart conditions and severe hypertension. The decongestant component, Phenylephrine, may affect blood pressure. The presence of Phenylephrine means the medicine should be used with caution when there are pre-existing conditions like high blood pressure.


Q: How quickly does Tusq DX start working after the first dose?

Official product descriptions indicate that the medicine is formulated to have a rapid onset of action. The effects of the components are typically described as occurring relatively rapidly after the first dose.


Q: How long does the effect of one dose of Tusq DX usually last?

The dosing instructions provided in the official documentation for the standard formulation recommend administering the dose every 4 hours. This time interval is the general indicator for the expected duration of the medicine’s effect.


Q: Is Tusq DX available without a prescription in some places?

This medicine is broadly classified as a multi-component cold and cough relief agent. In many regions, the formula is available over-the-counter (OTC) without a prescription, though local regulations or the specific concentration may require pharmacist consultation or behind-the-counter access.


Q: Does Tusq DX have any ingredients that are known to cause addiction?

The cough suppressant component, Dextromethorphan, is categorized as a non-narcotic antitussive. Official documents do not define this medicine as having addictive properties when used for the temporary relief of symptoms as outlined in official labeling.


Q: What happens if I miss a scheduled dose of Tusq DX?

Official patient information advises that if a dose is missed, it can be taken when it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped to limit total daily intake, and the user returns to the regular schedule.


Q: Can Tusq DX cause stomach upset or nausea?

Yes. Nausea, vomiting, and other gastrointestinal disturbances, such as heartburn, are included among the officially documented side effects of this medicine. If any documented side effects become severe or persistent, it is an official signal to seek further professional evaluation.


Q: Is it true that Tusq DX is sometimes used for allergy symptoms?

Yes. The medicine contains an antihistamine, Chlorpheniramine, which is included specifically to help relieve common allergy-related symptoms, such as runny nose and sneezing, that often occur alongside a cold or cough.


Q: What if I take Tusq DX but my cough doesn't get better?

Official guidance advises that if symptoms do not improve within 7 days of taking the medicine, official guidance indicates that consultation with a healthcare provider is generally warranted. New symptoms such as fever, rash, or persistent headache are also official signals that a professional evaluation is appropriate.


Q: Are there any specific foods or drinks to avoid when using Tusq DX?

Official documents advise avoiding or limiting certain substances due to potential interactions. This includes avoiding Grapefruit or Grapefruit juice, which may interact with the Dextromethorphan component, and using caution with alcohol and other Central Nervous System (CNS) depressants.


Q: Can people with asthma or COPD use Tusq DX?

Official labeling indicates that this medicine is not intended to treat a cough caused by lower respiratory tract conditions such as asthma or emphysema. Regulatory guidelines advise that individuals with these chronic conditions need to be evaluated before using this medicine.


Q: How common are serious side effects with Tusq DX?

Serious side effects, such as severe hypersensitivity reactions or severe cardiovascular events, are officially documented in the safety profile. However, these serious adverse events are typically considered to be rare occurrences when compared to the common, generally milder side effects reported.

How should Tusq DX be stored and disposed of?

How to Store and Dispose of Tusq DX? (Official Regulatory Information)

Official Storage Requirements

Tusq DX must be stored at a temperature not exceeding 30 C and kept in a dry place. It is essential to protect the medicine from light and avoid storage near direct sunlight or heat. The medicine must remain in its original container, tightly closed, until disposal.

Child-Safety and Handling

For safety, the product must be stored out of the reach of children and pets at all times. Avoid storing the medicine in high-moisture areas, such as a bathroom.

Official Disposal Instructions

Disposal of unused or expired Tusq DX should prioritize an immediate drug take-back program. If a take-back option is unavailable, the medicine must be disposed of via household trash. This involves mixing the medicine with an unappealing substance (like dirt or used coffee grounds), sealing it in a plastic bag or container, and placing it in the trash. Tusq DX is not recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tusq DX found in:

A-Z Index: